Health Care · Biological Products, (No Diagnostic Substances) · Nasdaq · CIK 1590877 · FYE Dec 31 · Prices AT CLOSE 2026-08-19 (USD) Last $12.02 · Day +8.58% · Mkt cap $731M · 1Y +49.7% · Off 52W high −25.8% · Vol (1Y) 90.4% Price2023-08-21 → 2026-08-19 RGNX close: $18.1 on 2023-08-21 to $12.0 on 2026-08-19. Split-adj closes · 240 of 2,744 · price returnⓘ At a glance | Short interest10.9% of sh out | | Days to cover3.8d | | 13F net flow (QoQ)+2.00% | | Top-10 13F concentration61.6% | | Next report (est.)2026-11-01 |
SI 2026-07-31 · 13F 2026-Q1ⓘ Key fundamentalsFY 2025 | Sales (TTM)$174.5M | | Earnings (TTM)-$196.4M | | ROE−107.0% | | Net margin−113.8% | | ROIC−94.2% | | Sales growth 3Y14.8% |
FY ratios · TTM sales/earnings (USD)ⓘ Trailing returns | YTD−16.5% | | 1Y+49.7% | | 3Y−33.7% | | 5Y−58.7% | | 10Y−5.2% | | Since incept. (ann.)−8.2% |
Total return · from 2015-09-17ⓘ Risk | Ann. volatility (1Y)90.4% | | Ann. volatility (3Y)80.7% | | Sharpe (1Y)0.83 | | Sharpe (3Y)0.25 | | Max drawdown (1Y)−64.6% | | Max drawdown (3Y)−78.4% | | Beta (3Y vs SPY)1.58 |
Daily returns, ann.ⓘ Top institutional holders13F 2026-Q1 | Manager | Shares | Value | % sh out | QoQ |
|---|
| BlackRock, Inc. | 5.8M | $48M | 11.20% | +0.5% | | Redmile Group, LLC | 4.4M | $37M | 8.46% | +0.0% | | JPMORGAN CHASE & CO | 3.5M | $27M | 6.75% | −2.0% | | STATE STREET CORP | 2.7M | $23M | 5.29% | +19.4% | | MORGAN STANLEY | 2.1M | $17M | 4.00% | +2.5% | | VANGUARD CAPITAL MANAGEMENT LLC | 2.0M | $17M | 3.89% | new | | GOLDMAN SACHS GROUP INC | 1.8M | $15M | 3.56% | +3.0% | | Integral Health Asset Management, LLC | 1.5M | $13M | 2.91% | +25.0% |
Δ vs 2025-Q4ⓘ Latest reported quarterslast report 2026-08-06 | Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|
| 2026-06-30 | 2026-08-06 | $0.43 | — | $108.0M | +405.7% | | 2026-03-31 | 2026-05-14 | −$1.72 | −1533.3% | $6.4M | −92.8% | | 2025-12-31 | 2026-03-05 | — | — | $30.3M | +43.0% | | 2025-09-30 | 2025-11-06 | −$1.20 | — | $29.7M | +22.9% |
As-reported XBRL · next 2026-11-01 est.ⓘ Segment mixFY2025 (ended Dec 2025) License And Service 36% · Zolgensma And Itvisma Royalties 19% · Zolgensma Royalties 19% · Nippon Shinyaku Licenses 17% · Total Service Revenue 3% product & service · TAGGED revenueⓘ Basis & disclosures - EOD closes · nothing imputed or averaged · absent “—”
- As-of differs by block · 13F = US long, 45+d lag, LOWER bound
- Not investment advice · no recommendation, price target or solicitation
- EDGAR + foreign registers · marketstack (licensed EOD) · spzco.com/methodology
| 
